Eslam Elkhadrawy/LinkedIn
Jan 28, 2026, 11:45
Eslam Elkhadrawy on Heparin-Induced Thrombocytopenia
Eslam Elkhadrawy, Product Specialist at Inspire Pharma Egypt, shared on LinkedIn:
”Heparin-Induced Thrombocytopenia (HIT):
When anticoagulation paradoxically causes thrombosis
HIT is a severe immune-mediated adverse drug reaction in which heparin exposure leads to thrombocytopenia accompanied by a high risk of thrombosis, rather than bleeding.
The condition is driven by IgG antibodies against the heparin–platelet factor 4 (PF4) complex, resulting in platelet activation and excessive thrombin generation.
Key message:
In HIT, thrombocytopenia reflects platelet activation and consumption, not impaired hemostasis.
References
Greinacher A. NEJM, 2015
Warkentin TE. Circulation, 2015”
Stay updated with Hemostasis Today.
-
Mar 14, 2026, 19:28Vishnu Priya Pulipati: Statins Beyond Cholesterol for Plaque Biology and Cardiovascular Risk Reduction
-
Mar 14, 2026, 19:19Yunpeng Xue: Humbled and Honored to Receive the 2025 Eberhard F. Mammen Young Investigator Award
-
Mar 14, 2026, 19:13Abhilasha Singh: A Novel Mechanism of Cardiac Aging and Disruption of The Neurovascular Network
-
Mar 14, 2026, 19:08Saleh Owimer: The Critical Rules of Safe Blood Transfusion
-
Mar 14, 2026, 19:01Omar Adwan: Correcting Lipemic Samples in CBC Using the Plasma Replacement Method
-
Mar 14, 2026, 16:28Abdul Mannan: Advancing VWF Activity Testing Beyond VWF:RCo in Clinical Laboratories
-
Mar 14, 2026, 16:26Rida Fatima: When The Body’s Most Vital Production Unit Stops Working
-
Mar 14, 2026, 16:16Martin Haluzík: Metabolic Risk Factors and Therapeutic Opportunities in Cardiovascular Disease
-
Mar 14, 2026, 16:10Raffaella Colombatti: Proud to Have Authored the New Lancet Seminar on Sickle Cell Disease